After a third review of safety data, an independent board recommended two trials of simufilam for Alzheimer's continue without modification.| Alzheimer's News Today
Nearly half of some 200 mild-to-moderate Alzheimer’s patients treated with oral simufilam for one year showed gains in cognitive tests.| Alzheimer's News Today
Cassava Sciences will discontinue developing simufilam for mild to moderate Alzheimer’s disease by the end of the second quarter of this year after the experimental treatment failed to meet key Phase 3 trial goals for improving cognition and daily function. In REFOCUS-ALZ (NCT05026177), patients treated with simufilam showed no significant improvements in cognitive functioning, as […] The post Simufilam fails to meet Phase 3 trial goals; development discontinued appeared first on Alzheime...| Alzheimer's News Today – The Web's Daily Resource for Alzheimer's News
A total of 1,929 Alzheimer's patients have enrolled in two simufilam studies, which the FDA said could support its application for approval.| Alzheimer's News Today